Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review

키워드

참고문헌 (92)

1. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
2. Michael H. Le, "2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis", Clinical Gastroenterology and Hepatology, 20(12), pp.2809~2817.e28 (2022), Elsevier BV[DOI]
3. Powell EE, "Non-alcoholic fatty liver disease", Lancet, 397, pp.2212~2224 (2021)
4. Sheka AC, "Nonalcoholic steatohepatitis : a review", JAMA, 323, pp.1175~1183 (2020)
5. Ginès P, "Liver cirrhosis", Lancet, 398, pp.1359~1376 (2021)
6. Giulio Marchesini, "Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)", Nutrition, Metabolism and Cardiovascular Diseases, 32(1), pp.1~16 (2022), Elsevier BV[DOI]
7. Loomba R, "Mechanisms and disease consequences of nonalcoholic fatty liver disease", Cell, 184, pp.2537~2564 (2021)
8. Firneisz G, "Non-alcoholic fatty liver disease and type 2 diabetes mellitus : the liver disease of our age?", World J Gastroenterol, 20, pp.9072~9089 (2014)
9. Lonardo A, "Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?", J Hepatol, 68, pp.335~352 (2018)
10. Targher G, "The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments", Nat Rev Gastroenterol Hepatol, 18, pp.599~612 (2021)
11. Mantovani A, "Non-alcoholic fatty liver disease and risk of incident diabetes mellitus : an updated meta-analysis of 501 022 adult individuals", Gut, 70, pp.962~969 (2021)
12. Allen AM, "The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity-a longitudinal cohort study", J Hepatol, 71, pp.1229~1236 (2019)
13. Rios RS, "Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma", Chin Med J(Engl), 134, pp.2911~2921 (2021)
14. Targher G, "Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus", Nat Rev Endocrinol, 14, pp.99~114 (2018)
15. Wijarnpreecha Karn, "Evaluation and Management of Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease", Clinical and Molecular Hepatology, 27(2), pp.221~235 (2021), 대한간학회[DOI]
16. Mantovani A, "Nonalcoholic fatty liver disease and risk of incident type 2 diabetes : a metaanalysis", Diabetes Care, 41, pp.372~382 (2018)
17. undefined, "EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease", Journal of Hepatology, 64(6), pp.1388~1402 (2016), Elsevier BV[DOI]
18. Eslam M, "A new definition for metabolic dysfunctionassociated fatty liver disease : an international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
19. Zheng KI, "From NAFLD to MAFLD: a “redefining” moment for fatty liver disease", Chin Med J(Engl), 133, pp.2271~2273 (2020)
20. Zheng KI, "Clinical utility of the MAFLD definition", J Hepatol, 74, pp.989~991 (2021)
21. Wang TY, "Metabolic(dysfunction)associated fatty liver disease : more evidence and a bright future", Hepatobiliary Surg Nutr, 10, pp.849~852 (2021)
22. Mohammed Eslam, "MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease", Gastroenterology, 158(7), pp.1999~2014.e1 (2020), Elsevier BV[DOI]
23. Sun DQ, "MAFLD and risk of CKD", Metabolism, 115, pp.154433~ (2021)
24. Liu HH, "Metabolicassociated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome : a matched casecontrol study", Hepatol Int, 15, pp.1337~1346 (2021)
25. Lonardo A, "Nonalcoholic fatty liver disease and COPD : is it time to cross the diaphragm?", Eur Respir J, 49, pp.1700546~ (2017)
26. Miao L, "Metabolic dysfunction-associated fatty liver disease is associated with greater impairment of lung function than nonalcoholic fatty liver disease", J Clin Transl Hepatol, 10, pp.230~237 (2022)
27. Wang TY, "Association of metabolic dysfunction-associated fatty liver disease with kidney disease", Nat Rev Nephrol, 18, pp.259~268 (2022)
28. Zheng KI, "The uprising of metabolic dysfunctionassociated fatty liver disease(MAFLD)in acute-on-chronic liver failure(ACLF)", Hepatobiliary Surg Nutr, 10, pp.857~859 (2021)
29. Chalasani N, "The diagnosis and management of non-alcoholic fatty liver disease : practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association", Am J Gastroenterol, 107, pp.811~826 (2012)
30. Kim D, "Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States", J Hepatol, 75, pp.1284~1291 (2021)
31. Parker BM, "Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery", BMC Obes, 4, pp.32~ (2017)
32. Sanyal AJ, "Prospective study of outcomes in adults with nonalcoholic fatty liver disease", N Engl J Med, 385, pp.1559~1569 (2021)
33. Ferguson D, "Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus", Nat Rev Endocrinol, 17, pp.484~495 (2021)
34. Gross B, "PPARs in obesityinduced T2DM, dyslipidaemia and NAFLD", Nat Rev Endocrinol, 13, pp.36~49 (2017)
35. Smati S, "Anti-diabetic drugs and NASH : from current options to promising perspectives", Expert Opin Investig Drugs, 30, pp.813~825 (2021)
36. Petroni ML, "Management of non-alcoholic fatty liver disease", BMJ, 372, pp.m4747~ (2021)
37. Mantovani A, "Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease : a systematic review", Lancet Gastroenterol Hepatol, 7, pp.367~378 (2022)
38. Han X, "Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis", Pharmacol Ther, 222, pp.107791~ (2021)
39. Francque S, "Nonalcoholic steatohepatitis : the role of peroxisome proliferator-activated receptors", Nat Rev Gastroenterol Hepatol, 18, pp.24~39 (2021)
40. Pawlak M, "Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease", J Hepatol, 62, pp.720~733 (2015)
41. Vázquez-Carrera M, "Unraveling the effects of PPARβ", δ on insulin resistance and cardiovascular disease, 2016, pp.27, 319~334
42. Li Y, "Molecular recognition of nitrated fatty acids by PPAR gamma", Nat Struct Mol Biol, 15, pp.865~867 (2008)
43. Cipolletta D, "PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells", Nature, 486, pp.549~553 (2012)
44. Wettstein G, "The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis", Hepatol Commun, 1, pp.524~537 (2017)
45. Lefere S, "Differential effects of selective-and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆", J Hepatol, 73, pp.757~770 (2020)
46. Francque SM, "A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH", N Engl J Med, 385, pp.1547~1558 (2021)
47. Boyer-Diaz Z, "Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease", J Hepatol, 74, pp.1188~1199 (2021)
48. Kotsiliti E, "Lanifibranor and NASH resolution", Nat Rev Gastroenterol Hepatol, 18, pp.832~ (2021)
49. Ratziu V, "Elafibranor, an agonist of the peroxisome proliferatoractivated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening", Gastroenterology, 150, pp.1147~1159 (2016)
50. Cariou B, "Dual peroxisome proliferator-activated receptor α", δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects, 2013, pp.36, 2923~2930
51. Staels B, "Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha", delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease, Hepatology, pp.2013, 58[DOI]
52. "GENFIT: Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis"[URL]
53. Jani RH, "Pharmacokinetics, safety, and tolerability of saroglitazar(ZYH1), a predominantly PPARαagonist with moderate PPARγ agonist activity in healthy human subjects", Clin Drug Investig, 33, pp.809~816 (2013)
54. Kaul U, "New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease : integrated analysis of the real world evidence", Cardiovasc Diabetol, 18, pp.80~ (2019)
55. Gawrieh S, "Saroglitazar, a PPAR-α", γ agonist, for treatment of NAFLD : a randomized controlled double-blind phase 2 trial, 2021, pp.74, 1809~1824
56. DeFronzo RA, "Pioglitazone : the forgotten, cost-effective cardioprotective drug for type 2 diabetes", Diab Vasc Dis Res, 16, pp.133~143 (2019)
57. Byrne CD, "Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications", Diabetes Obes Metab, 24(Suppl 2), pp.28~43 (2022)
58. Cusi K, "Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus : a randomized trial", Ann Intern Med, 165, pp.305~315 (2016)
59. Vaccaro O, "Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin(TOSCA. IT) : a randomised, multicentre trial", Lancet Diabetes Endocrinol, 5, pp.887~897 (2017)
60. Lian J, "Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis", Front Endocrinol(Lausanne), 12, pp.615409~ (2021)
61. Cariou B, "Thiazolidinediones and PPARγagonists : time for a reassessment", Trends Endocrinol Metab, 23, pp.205~215 (2012)
62. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
63. Drucker DJ, "Mechanisms of action and therapeutic application of glucagon-like peptide-1", Cell Metab, 27, pp.740~756 (2018)
64. Patel Chavez C, "The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD", J Clin Endocrinol Metab, 107, pp.29~38 (2022)
65. Young AA, "Glucose-lowering and insulin-sensitizing actions of exendin-4 : studies in obese diabetic(ob", ob, db, Diabetes, pp.1999, 48[DOI]
66. Andersen A, "Glucagon-like peptide 1 in health and disease", Nat Rev Endocrinol, 14, pp.390~403 (2018)
67. Kim ER, "A GLP-1", GLP-2 receptor dual agonist to treat NASH : targeting the gut-liver axis and microbiome, 2022, pp.75, 1523~1538
68. Panjwani N, "GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-", -)mice, 2013, pp.154, 127~139
69. Mantovani A, "GLP-1 receptor agonists and reduction of liver fat content in NAFLD patients : just a question of weight loss?", Dig Liver Dis, 53, pp.1673~1674 (2021)
70. Gastaldelli A, "Time for glucagon like peptide-1receptor agonists treatment for patients with NAFLD?", J Hepatol, 64, pp.262~264 (2016)
71. Mantovani A, "Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis : an updated meta-analysis of randomized controlled trials", Metabolites, 11, pp.73~ (2021)
72. Capehorn MS, "Efficacy and safety of once-weekly semaglutide 1. 0mg vs once-daily liraglutide 1. 2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes(SUSTAIN 10)", Diabetes Metab, 46, pp.100~109 (2020)
73. Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
74. Lim S, "Glucagon-like peptide-1 receptor agonists and cardiovascular events : class effects versus individual patterns", Trends Endocrinol Metab, 29, pp.238~248 (2018)
75. Armstrong MJ, "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN) : a multicentre, double-blind, randomised, placebo-controlled phase 2 study", Lancet, 387, pp.679~690 (2016)
76. Wang L, "Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease : a systematic review and meta-analysis of randomized controlled trials", Pharmacol Res, 171, pp.105765~ (2021)
77. Mulvihill EE, "Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors", Endocr Rev, 35, pp.992~1019 (2014)
78. Avogaro A, "The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications", Diabetes Care, 37, pp.2884~2894 (2014)
79. Balaban YH, "Dipeptidyl peptidase IV(DDP IV)in NASH patients", Ann Hepatol, 6, pp.242~250 (2007)
80. Engel SS, "Safety and tolerability of sitagliptin in type 2 diabetes : pooled analysis of 25 clinical studies", Diabetes Ther, 4, pp.119~145 (2013)
81. Alam S, "Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients : a 1-year randomized control trial", Hepat Med, 10, pp.23~31 (2018)
82. Yan J, "Liraglutide, sitagliptin, and insulin glargine added to metformin : the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease", Hepatology, 69, pp.2414~2426 (2019)
83. Kosi-Trebotic L, "Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients", Eur J Clin Invest, 47, pp.829~838 (2017)
84. Cui J, "Sitagliptin vs. placebo for non-alcoholic fatty liver disease : a randomized controlled trial", J Hepatol, 65, pp.369~376 (2016)
85. Joy TR, "Sitagliptin in patients with non-alcoholic steatohepatitis : a randomized, placebo-controlled trial", World J Gastroenterol, 23, pp.141~150 (2017)
86. Duez H, "DPP-4 inhibitors in the treatment of type 2 diabetes", Biochem Pharmacol, 83, pp.823~832 (2012)
87. Hussain M, "Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease", Pak J Med Sci, 32, pp.1396~1401 (2016)
88. Chao EC, "SGLT2 inhibition--a novel strategy for diabetes treatment", Nat Rev Drug Discov, 9, pp.551~559 (2010)
89. Wei Q, "Effect of SGLT2 inhibitors on type 2diabetes mellitus with non-alcoholic fatty liver disease: a metaanalysis of randomized controlled trials", Front Endocrinol(Lausanne), 12, pp.635556~ (2021)
90. Ala M, "SGLT2 inhibition for cardiovascular diseases, chronic kidney disease, and NAFLD", Endocrinology, 162, pp.157~ (2021)
91. Mantovani A, "Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease : a meta-analysis of randomized controlled trials", Metabolites, 11, pp.22~ (2020)
92. Takahashi H, "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD", Hepatol Commun, 6, pp.120~132 (2022)

관련 논문AI추천